April 25, 2022
Dr Diana Isaacs provides insight on current challenges in the clinical treatment of patients with diabetes and shares clinical pearls for the use of CGMs in disease management.
April 25, 2022
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, evaluates upcoming CGM advances in the pipeline for the management of diabetes.
April 18, 2022
Dr Diana Isaacs reviews the significance of Eversense’s recent approval for a 180-day indication and the potential role of Dexcom G7 in the diabetes treatment landscape.
April 18, 2022
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, comments on the accuracy and selection of CGMs in treating diabetes and shares insight on the evolution of CGM systems over the past year.
April 11, 2022
An expert in diabetes management discusses the role of CGMs in treating diabetes during the COVID-19 pandemic and the benefits of using CGM in telemedicine.
April 11, 2022
Dr Diana Isaacs provides insight on patient factors to consider for CGM use in diabetes treatment.
April 11, 2022
Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, reviews the advantages of CGMs in treating type 1 and type 2 diabetes and how CGMs can improve glycemic control and quality of life in patients.